TCI GENE Inc. (TPEX:6879)
Taiwan · Delayed Price · Currency is TWD 36.30
-0.20 (-0.55%)
Jan 22, 2026, 11:16 AM CST
TCI GENE Revenue
TCI GENE had revenue of 141.71M TWD in the half year ending June 30, 2025, a decrease of -5.44%. This brings the company's revenue in the last twelve months to 324.73M, down -6.82% year-over-year. In the year 2024, TCI GENE had annual revenue of 347.54M with 4.10% growth.
Revenue (ttm)
324.73M
Revenue Growth
-6.82%
P/S Ratio
2.84
Revenue / Employee
n/a
Employees
n/a
Market Cap
922.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 347.54M | 13.68M | 4.10% |
| Dec 31, 2023 | 333.86M | -90.17M | -21.26% |
| Dec 31, 2022 | 424.02M | -8.20M | -1.90% |
| Dec 31, 2021 | 432.22M | 239.27M | 124.01% |
| Dec 31, 2020 | 192.95M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals Co., LTD. | 21.10B |
| Lotus Pharmaceutical | 18.66B |
| PharmaEssentia | 13.82B |
| Center Laboratories | 1.57B |
| Oneness Biotech | 117.33M |
| Polaris Group | 70.83M |
| Lumosa Therapeutics | 42.59M |
| Caliway Biopharmaceuticals | 34.99M |